Walleye Capital LLC Grows Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Walleye Capital LLC grew its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 264.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 280,299 shares of the biotechnology company's stock after acquiring an additional 203,331 shares during the quarter. Walleye Capital LLC owned about 0.18% of Ironwood Pharmaceuticals worth $1,155,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its position in Ironwood Pharmaceuticals by 6.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 85,577 shares of the biotechnology company's stock valued at $746,000 after purchasing an additional 4,993 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 8,156 shares during the last quarter. CWM LLC grew its position in Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock worth $43,000 after acquiring an additional 2,345 shares in the last quarter. SG Americas Securities LLC increased its stake in Ironwood Pharmaceuticals by 78.9% during the second quarter. SG Americas Securities LLC now owns 18,769 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 8,277 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Ironwood Pharmaceuticals by 7.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 59,967 shares of the biotechnology company's stock valued at $391,000 after purchasing an additional 4,100 shares during the period.

Ironwood Pharmaceuticals Trading Up 2.7 %

Shares of IRWD traded up $0.09 during trading hours on Friday, reaching $3.43. 2,952,455 shares of the company traded hands, compared to its average volume of 2,843,546. The stock's fifty day moving average price is $4.06 and its 200 day moving average price is $5.09. The firm has a market cap of $548.90 million, a price-to-earnings ratio of -114.33 and a beta of 0.41. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.06 and a 12-month high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million during the quarter, compared to analysts' expectations of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Ironwood Pharmaceuticals's quarterly revenue was down 19.4% on a year-over-year basis. During the same period last year, the firm earned $0.12 earnings per share. On average, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the firm's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the transaction, the chief financial officer now owns 309,572 shares of the company's stock, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IRWD shares. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a "hold" rating in a report on Monday, September 9th. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Craig Hallum dropped their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, August 9th. Finally, Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a "market perform" rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.40.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.